Vedanta Biosciences Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#2164

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Vedanta Biosciences's estimated annual revenue is currently $27.7M per year.(i)
  • Vedanta Biosciences received $27.0M in venture funding in December 2018.
  • Vedanta Biosciences's estimated revenue per employee is $193,750
  • Vedanta Biosciences's total funding is $301.6M.

Employee Data

  • Vedanta Biosciences has 143 Employees.(i)
  • Vedanta Biosciences grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

The trillions of microbes that call us home the human microbiome - perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

keywords:Biotechnology,Healthcare,Pharmaceuticals

$301.6M

Total Funding

143

Number of Employees

$27.7M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vedanta Biosciences News

2022-04-17 - Human Microbiome Market Size And Forecast | Enterome ...

Human Microbiome Market Size And Forecast | Enterome Bioscience, ... Osel Second Genome Vithera Pharmaceuticals, Vedanta Biosciences, Inc.

2022-04-13 - Vedanta Biosciences Publishes Phase 1a/1b Results for Lead ...

Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated...

2022-04-06 - Overt Hepatic Encephalopathy Market is Booming Worldwide. The market size is supposed to increase at a decent compound annual growth rate (CAGR) during the Study Period [2019-2032], Evaluates DelveInsight

Several key pharmaceutical companies, including Axcella Health, Inc., Vedanta Biosciences, Patricia Bloom, Salix Pharmaceuticals,...

2021-10-05 - Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...

2021-10-05 - Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the pr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.7M1437%$120M
#2
$15M14410%N/A
#3
$27.9M144-26%$367M
#4
$28.1M14525%$173M
#5
$32.2M14531%N/A

Vedanta Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-06-07$50.0MUndisclosedArticle
2018-12-26$27.0MCMultipleArticle